ANP32B and acute myeloid leukemia: To further investigate the impact of ANP32B on the viability of AML cells in mice, we initially labeled MV4-11 cells with luciferase and subsequently administered ANP32B-targeted shRNA and sh-NC AML cells into NSG mice via the tail vein (Fig. 4A).